393 related articles for article (PubMed ID: 32964970)
1. Correlation between microRNA-766 expression in patients with advanced gastric cancer and the efficacy of platinum-containing chemotherapy.
Xue YF; Xue D; Yao B; Hu CG; Liu J
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8822-8829. PubMed ID: 32964970
[TBL] [Abstract][Full Text] [Related]
2. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
3. Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Fanotto V; Fornaro L; Bordonaro R; Rosati G; Rimassa L; Di Donato S; Santini D; Tomasello G; Leone F; Silvestris N; Stragliotto S; Scartozzi M; Giampieri R; Nichetti F; Antonuzzo L; Cinieri S; Avallone A; Pellegrino A; Melisi D; Vasile E; Gerratana L; Aprile G
J Geriatr Oncol; 2019 Jul; 10(4):591-597. PubMed ID: 30551958
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Stenholm L; Stoehlmacher-Williams J; Al-Batran SE; Heussen N; Akin S; Pauligk C; Lehmann S; Senff T; Hofheinz RD; Ehninger G; Kramer M; Goekkurt E
Ann Oncol; 2013 Oct; 24(10):2581-2588. PubMed ID: 23975664
[TBL] [Abstract][Full Text] [Related]
5. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
6. Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer.
Zhang Q; Li K; Xu JH; Zhao CG; Gao Q; Wu B; Liu XY
World J Gastroenterol; 2013 Oct; 19(39):6630-6. PubMed ID: 24151392
[TBL] [Abstract][Full Text] [Related]
7. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study.
Maeda O; Matsuoka A; Miyahara R; Funasaka K; Hirooka Y; Fukaya M; Nagino M; Kodera Y; Goto H; Ando Y
World J Gastroenterol; 2017 Feb; 23(6):1090-1097. PubMed ID: 28246483
[TBL] [Abstract][Full Text] [Related]
8. Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort.
Ekheden I; Ebrahim F; Ólafsdóttir H; Raaschou P; Wettermark B; Henriksson R; Ye W
Eur J Clin Pharmacol; 2020 Jul; 76(7):1029-1041. PubMed ID: 32372150
[TBL] [Abstract][Full Text] [Related]
9. [Progress in chemotherapy for advanced gastric cancer].
Xu RH; Teng KY
Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
[TBL] [Abstract][Full Text] [Related]
10. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer.
Liu P; Chen J; Zhao L; Hollebecque A; Kepp O; Zitvogel L; Kroemer G
Oncoimmunology; 2022; 11(1):2093518. PubMed ID: 35769948
[TBL] [Abstract][Full Text] [Related]
11. Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy.
Xu S; Li J; Chen L; Guo L; Ye M; Wu Y; Ji Q
Medicine (Baltimore); 2019 Oct; 98(42):e17335. PubMed ID: 31626089
[TBL] [Abstract][Full Text] [Related]
12. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
13. The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy.
Wu X; Zhou F; Ji X; Ren K; Shan Y; Mao X; Fen Y; Chen R; Ding H; Fu X
Future Oncol; 2017 Dec; 13(29):2691-2696. PubMed ID: 28972404
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
[TBL] [Abstract][Full Text] [Related]
15. TP53 Codon 72 Polymorphism Predicts Efficacy of Paclitaxel Plus Capecitabine Chemotherapy in Advanced Gastric Cancer Patients.
Zha Y; Gan P; Liu Q; Yao Q
Arch Med Res; 2016 Jan; 47(1):13-8. PubMed ID: 26696550
[TBL] [Abstract][Full Text] [Related]
16. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
[TBL] [Abstract][Full Text] [Related]
17. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
[TBL] [Abstract][Full Text] [Related]
18. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
19. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
